Enter multiple symbols separated by commas

Schering-Plough Beats Earnings Forecasts By Wide Margin

Schering-Plough reported strong first-quarter results, surpassing consensus estimates by a wide margin due to strong sales of cholesterol drugs and allergy treatments.

Schering-Plough on Thursday morning announced first-quarter earnings growth of 55%, beating analysts' estimates on sharply higher sales of its prescription drugs, including two cholesterol fighters sold in partnership with Merck .

Profit rose 55% to $543 million, or 36 cents a share, from $350 million, or 24 cents a share, in the year-ago period.

Excluding one-time items, the Kenilworth, N.J.-based pharmaceutical company reported earnings of 42 cents a share. Analysts expected Schering-Plough to report 29 cents a share, according to Thomson Financial.

Sales in the period jumped 17% over last year to $3.0 billion before revenue from cholesterol drugs Vytorin and Zetia, which the drugmaker markets with Merck. Sales would have jumped 21% in the period including the co-marketed medicines.

Sales of allergy drugs Nasonex and Clarinex both came in above Wall Street estimates. The drugmaker also got a boost from arthritis treatment Remicade, which jumped 34% to $373 million in the first quarter. Schering-Plough sells Remicade outside of the U.S. and Japan under license from Johnson & Johnson.

"This was largely a quality revenue-driven beat," said Tim Anderson, pharma analyst with Prudential Equity Group. "The 'whisper' was that Schering-Plough could beat by a significant margin, and they did. Other drug companies have also beat thus far this quarter, and those that have yet to report will probably beat as well."

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video